×
Embecta SG&A Expenses 2021-2024 | EMBC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Embecta sg&a expenses from 2021 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
View More
Embecta SG&A Expenses 2021-2024 | EMBC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Embecta sg&a expenses from 2021 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Related Stocks
Company Name
Market
Cap
Elevance Health (ELV)
$91.4B
Cencora (COR)
$47.5B
DiDi Global (DIDIY)
$23.3B
Natera (NTRA)
$21.4B
ICON (ICLR)
$16.1B
Viatris (VTRS)
$15.6B
Avantor (AVTR)
$13.4B
Revvity (RVTY)
$13.4B
CochLear (CHEOY)
$12.8B
BioMerieux (BMXMF)
$12.7B
Solventum (SOLV)
$11.6B
Medpace Holdings (MEDP)
$9.8B
Doximity (DOCS)
$9.6B
Charles River Laboratories (CRL)
$9.5B
HealthEquity (HQY)
$9B
Sonic Healthcare (SKHHY)
$8.8B
Bausch + Lomb (BLCO)
$6.9B
Life Times (LTH)
$5.1B
Sotera Health (SHC)
$3.9B
Organon (OGN)
$3.8B
BrightSpring Health Services (BTSG)
$3.2B
Surgery Partners (SGRY)
$2.9B
PACS (PACS)
$2.6B
Concentras Parent (CON)
$2.6B
Ardent Health Partners (ARDT)
$2.4B
Premier (PINC)
$2.1B
Alignment Healthcare (ALHC)
$2.1B
Ryman Healthcare (RYHTY)
$2B
GeneDx Holdings (WGS)
$2B
GoodRx Holdings (GDRX)
$1.6B